Skip to search formSkip to main contentSkip to account menu

mycophenolate mofetil

Known as: MMF, mofetil mycophenolate, 2-Morpholinoethyl (e)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate 
The morpholinoethyl ester of mycophenolic acid (MPA) with potent immunosuppressive properties. Mycophenolate stops T-cell and B-cell proliferation… 
National Institutes of Health

Related topics

Related topics

20 relations
Anti-Inflammatory Agents, Non-SteroidalAntineoplastic AgentsDecreased Immunologic Activity [PE]Drug Allergy

Narrower (2)

CellceptRS 61443

Broader (1)

Immunosuppressive Agents

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2005
Highly Cited
2005
Cyclosporine withdrawal from a mycophenolate mofetil-containing immunosuppressive regimen: results of a five-year, prospective, randomized study.
Maintenance immunosuppression with cyclosporine (CsA) is associated with nephrotoxicity, hyperlipidemia, and hypertension. This… 
Highly Cited
2005
Highly Cited
2005
Sirolimus in Combination with Tacrolimus Is Associated with Worse Renal Allograft Survival Compared to Mycophenolate Mofetil Combined with Tacrolimus
Cyclosporine (CsA) nephrotoxicity is enhanced by sirolimus (SRL). Tacrolimus is perceived to be less nephrotoxic than CsA, and… 
Review
2003
Review
2003
Mycophenolate Mofetil for Solid Organ Transplantation: Does the Evidence Support the Need for Clinical Pharmacokinetic Monitoring?
The need for clinical pharmacokinetic monitoring (CPM) of the immunosuppressant mycophenolate mofetil (MMF) has been debated… 
Highly Cited
2002
Highly Cited
2002
A prospective randomized trial of mycophenolate mofetil in liver transplant recipients with hepatitis C
Hepatitis C is the most common indication for liver transplantation (LT) in the United States. Recurrence of hepatitis C virus… 
Highly Cited
2001
Highly Cited
2001
Control of antidonor antibody production with tacrolimus and mycophenolate mofetil in renal allograft recipients with chronic rejection.
BACKGROUND In renal transplantation, chronic rejection is a major cause of late allograft loss. Recent studies indicate that a… 
Highly Cited
2000
Highly Cited
2000
Pharmacodynamic Monitoring of Mycophenolate Mofetil
Abstract The immunosuppressive activity of Mycophenolate Mofetil (MMF) is based on the reversible inhibition of inosine-5… 
Highly Cited
1999
Highly Cited
1999
The kinetics of mycophenolic acid and its glucuronide metabolite in adult kidney transplant recipients
Highly Cited
1998
Highly Cited
1998
Psoriasis vulgaris treated successfully with mycophenolate mofetil
Mycophenolate mofetil (MMF) is a new immunosuppressive drug which non‐competitively and reversibly blocks the de novo synthesis… 
Highly Cited
1998
Highly Cited
1998
Low-dose cyclosporine and mycophenolate mofetil in renal allograft recipients with suboptimal renal function.
BACKGROUND Cyclosporine (CsA) nephrotoxicity can be identified by functional changes and chronic renal damage. CsA-associated… 
Highly Cited
1997
Highly Cited
1997
Steroid withdrawal in mycophenolate mofetil-treated renal allograft recipients.
BACKGROUND Acute rejection is an inherent risk of the withdrawal of steroids in renal allograft recipients. Mycophenolate mofetil… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)